JOURNAL OF NANO- AND ELECTRONIC PHYSICS
Vol. **18** No 2, 02011(7pp) (2026)

ЖУРНАЛ НАНО- ТА ЕЛЕКТРОННОЇ ФІЗИКИ
Том **18** № 2, 02011(7cc) (2026)

REGULAR ARTICLE

Nanotechnology in Cancer Early Detection and Accurate Diagnosis: Advances in Nanotechnology, Technologies, and Clinical Applications

R.D.H. Devi[1,*] ✉, M. Dachawar[2,†], J.S. Priya[3,‡], S. Gowdhamkumar[4,§], Dr.S. Sivaranjani[5,**], D.D. Vijay[6]

[1] *Department of Artificial Intelligence and Data Science, Karpaga Vinayaga College of Engineering & Technology, Chengalpattu, Tamil Nadu, India*
[2] *Department of Computer Engineering, Vishwakarma University, Pune, Maharashtra, India*
[3] *Department of Master of Computer Applications, Sona College of Technology, Salem, India*
[4] *Training Department, PSG Industrial Institute (PSGCT), Peelamedu, Coimbatore, Tamilnadu, India*
[5] *Department of EEE, Sri Krishna College of Engineering and Technology, Coimbatore, India*
[6] *Department of Microbiology, Karpaga Vinayaga Institute of Medical Sciences & Research Centre, Chengalpattu, Tamil Nadu, India*

(Received 23 January 2026; revised manuscript received 23 April 2026; published online 29 April 2026)

Nanotechnology is one of such radical approaches in oncology that offers an unprecedented sensitivity and specificity in the detection and diagnosis of cancer in its early stages. This paper has evaluated in a systematic manner the diagnostic value of various nanomaterial-based systems that can be used to diagnose breast, lung, and colorectal cancer such as gold nanoparticles, quantum dots, magnetic nanoprobes, and graphene-based biosensors. The designed nanodiagnostic systems reached the detection limits of 110 pg/mL of major tumor biomarkers including CA15-3, CEA, and HER2 with an average diagnostic accuracy of 95.6 percent in all the analyzed samples. Nanotechnology-based biosensors had 3-5 times higher signal value and 40 percent shorter assay time compared to the conventional immunoassay biosensor. Further on, in vivo imaging with specific nanoparticles gave a tumor to background ratio of 4.8:1, which enabled the lesions to be observed at submillimeter resolution. Specificity of diagnosis was also improved by 12 when these nano-platforms were combined with machine learning algorithms. In general, the results prove that the application of nanotechnology-related diagnostic devices significantly increases the sensitivity, speed, and accuracy of cancer detection, reducing false-positive results and contributing to quick clinical decision-making. The outcomes of this study highlight the revolutionary capability of nanotechnology in enhancing precision oncology by providing early and precise and individual cancer diagnostics.

Keywords: Nanotechnology, Cancer diagnosis, Tumor biomarkers, Machine learning, Precision oncology, Diagnostic imaging.

DOI: 10.21272/jnep.18(2).02011 PACS numbers: 87.19.xj, 87.19.lv

1. INTRODUCTION

Cancer has been among the greatest health issues of concern in the world with almost 10 million deaths annually. In spite of the impressive growth of therapeutic advances, there is a still an issue of delayed diagnosis that complicates the treatment process and negatively influences the survival rate. Early diagnosis is needed in order to increase the prognosis, intervention at an early age, and reduce disease burden. Nevertheless, conventional diagnostic methods like histopathology, immunoassays and imaging methods have disadvantages such as low sensitivity, time consuming processes and poor ability to identify cancer biomarkers at extremely low levels. Such difficulties provide a clear picture of the necessity to implement innovative diagnostic technologies that would allow the fast, accurate, and highly sensitive detection of cancer at the molecular level [1-3].

Nanotechnology has become a revolutionary instrument in the field of biomedical science which presents distinctive physicochemical characteristics which can be accurately designed in disease identification, targeted therapy and imaging research. Nanomaterials including gold nanoparticles, quantum dots, magnetic nanoprobes and graphene-based biosensors are perfect choices because they have high surface reactivity, signal amplification and biocompatibility which qualify them to be used in ultrasensitive cancer diagnostics. These nanosystems

* Correspondence e-mail: delshi@rocketmail.com
† madhavi.dachawar@vupune.ac.in
‡ sujipriya@sonatech.ac.in
§ saigowdham@gmail.com
** sivaranjanis@skcet.ac.in

Cite this article as: R.D.H. Devi et al., *J. Nano- Electron. Phys.* 18 No 2, 02011 (2026) https://doi.org/10.21272/jnep.18(2).02011

can be functionallyized with particular ligands or antibodies, which enables selective recognition of tumor biomarkers, and therefore a specificity increases and reduction in false-positive outcomes. Besides, predictive modeling, pattern recognition, and data-driven optimization of diagnostic performance are enabled by the combination of nanotechnology and computational intelligence (AI) and machine learning (ML) tools.

Recent progress in nanodiagnostic technologies has yielded remarkable improvements in analytical sensitivity, real-time detection capability, and imaging precision. Nanoparticle-based biosensors have demonstrated detection limits several orders of magnitude lower than conventional methods, enabling identification of key tumor biomarkers – including CA15-3, CEA, and HER2 – at picogram-per-milliliter concentrations. Additionally, nanotechnology-enhanced imaging techniques have achieved superior tumor contrast and resolution, enabling early localization and characterization of malignant lesions [4-8].

Recent developments in nanodiagnostic technologies have provided outstanding advancement in the real-time detection ability, imaging precision and analytical sensitivity. The biosensors with nanoparticles have shown to be several orders of magnitude sensitive with the detection limits showing the ability to detect important tumor biomarkers such as CA15-3, CEA and HER2 at concentrations of picogram-per-milliliters. Also, imaging modalities have been improved through nanotechnology, which has led to high tumor contrast and resolution, and thus early localization and characterization of the malignant lesions.

The current paper discusses how different nanomaterial-based systems can be used in the early diagnosis of breast, lung, and colorectal cancer. Particularly, the efficiency of gold nanoparticles, quantum dots, magnetic nanoprobes, and graphene-based biosensors in diagnostics was considered in detail. Moreover, the combination of these nanosystems with machine learning algorithms was studied in order to improve the accuracy and specificity of diagnosis. The results of this study would serve to form a platform to the next generation of nanotechnology-based diagnostic systems, which can make a revolution in precision oncology with earlier, quicker, and more dependable cancer detection.

Nanotechnology has become a revolutionary sphere in cancer diagnostics being a new source of solutions to early detection and precise monitoring in the last decade. Traditional nanodiagnostic approaches have been mostly based on the production of nanoparticles, including gold nanoparticles, liposomes, magnetic nanoprobes, and quantum dots, to be used in biomarker detection, diagnostics imaging and delivery of drugs. These nanoplatforms have been found to be highly sensitive, signal amplification, and biocompatible than the conventional methods of diagnosing. Nevertheless, majority of the available literature has concentrated on individual systems of nanomaterials or individual cancer models with little comparative information among several types of cancer. Also, there are a number of issues that remain such as limited biomarker specificity, inconsistencies in reproducibility, complex synthesis instructions, and insufficient consideration with computational intelligence software to predictive data interpretation. Thus, the urgent intensification to establish multi-purpose, exceptionally specific, and information-driven nanodiagnostic systems that integrate experimental creativity with computational optimization in order to attain dependable, early, and clinically translatable cancer detection still exists [9-11].

The current work suggests a comprehensive nanotechnology-based diagnostic system which is a systematic assessment and comparison of four advanced nanomaterial systems, including gold nanoparticles, quantum dots, magnetic nanoprobes, and graphene-based biosensors in the early diagnosis of breast, lung, and colorectal cancer. Unlike in the past studies, this study is the first to provide a combination of experimental validation and machine learning-based optimization to enhance diagnostic accuracy and specificity. The nanodiagnostic systems that were developed had ultrasensitive detection limits of 110 pg/mL of the key cancer biomarkers, CA15-3, CEA, and HER2 and a total diagnostic accuracy of 95.6, a significant improvement over the standard immunoassay methods. Moreover, a multimodal diagnostic plan was developed through the combination of biosensing and in vivo imaging where high-resolution tumor images were realized through high signal to noise ratios. The integration of AI-based data analytics creates a new aspect of cancer diagnostics, which enables superior pattern recognition, multi-parametric data integration, and predictive evaluation of the biomarker expression dynamics. Altogether, the present research contributes to the evolution of nanodiagnostics, as it introduces a data-intelligent platform of comprehensive nanoscale biosensing, with computational accuracy. The suggested methodology is the basis of the next-generation cancer diagnostics with the potential to provide earlier diagnosis, more accurate diagnosis, and individual clinical decision-making in precision oncology. Although there has been a lot of progress in nanotechnology-based diagnostic platforms, they have not been translated into trustworthy clinical tools because of disjointed experimental methodology, small cohort, and not verified in real clinical settings. The existing studies do not often consider the integration of nanomaterial-based biosensors with computational decision-support systems, and the imaging of nanoparticles in vivo has a global lack of the tumor-to-background ratio and different types of cancer.

This paper fills these gaps by creating a comprehensive nanodiagnostic framework, a combination of high-performance nanomaterial sensors, such as gold nanoparticles, quantum dots, magnetic nanoprobes, and graphene-based biosensors, and machine learning-assisted classification. The system has a detection limit of 110 pg/mL, a diagnostic accuracy of 95.6, 3-5-fold increase in signal intensity, and 40 per cent cut in assay time. In vivo Imaging is 4.8:1 tumor to background, which can allow the visualization of submillimeter lesions, whereas the integration of AI increases specificity by 12. In general, the proposed platform will progress precision oncology because it offers more sensitive, accurate, and faster multimodal diagnostics of cancer [12-15].

The paper has been designed in a manner that gives a concise discussion on how nanotechnology-based diagnostic platforms can be developed, evaluated, and optimized towards the detection of early cancer. The background, motivation, and objectives are described in the section 2 by providing the potential of the nanotechnology to enhance diagnostic sensitivity and precision. Section 3 provides information about the materials, synthesis procedures and characterization of gold nanoparticles, quantum dots, magnetic nanoprobes and graphene-based biosensors. Section 4 outlines the experimental schemes of detecting biomarkers, analysis of images and synthesizing machine learning algorithms to improve the efficiency of diagnosis. Section 4.1 addresses the results, which include the improvement in detection limits, the signal amplification, and the diagnostic accuracy in general. The conclusion of the paper presents in Section 5.

2. LITERATURE SURVEY

The last decade was characterized by a substantial number of studies proving the fact that nanotechnology can be utilized in the development of cancer diagnostics. Das et al. (2023) have emphasized the application of carbon nanomaterial-based biosensors in detecting early-stage cancer because they are portable, biocompatible, and efficient in diagnosing the disease (RSC Advances). Britto et al. (2024) also explored the idea of multifunctional carbon-nanomaterial-based biosensors and demonstrated that the combination of nanomaterials could significantly increase sensitivity and specificity toward the detection of cancer biomarkers (Small Methods). Oyowvi (2025) devoted his attention to the ovarian cancer, showing how nanotechnology could revolutionize the process of early detection, diagnosis, and approaches to treatment (PMC). Wang et al. (2024) undertook an in-depth overview of nanotechnology in the diagnostics and management of malignant tumors with an emphasis on the role of nanoparticles in enhancing the level of contrast and diagnostic specificity (Signal Transduction and Targeted Therapy).

In the study of breast cancer diagnostics, Gopinath et al. (2023) discussed nanomaterial-assisted biosensors to establish the presence of important biomarkers in cancer at an early stage, noting their excellent ability to recognize targets and analyze them quickly (Current Pharmaceutical Design). In the same manner, Sethuraman et al. (2024) examined metal oxide nanoparticles as salivary biosensors to detect oral cancer, the study revealed that the non-invasive and highly sensitive oral cancer diagnostic approach is achievable (PMC). Zafar et al. (2025) summarized the emergent biomarkers in early cancer detection with significant focus on the use of bio-markers in the diagnosis of cancer, which is a reliable, fast, and non-invasive method (European Journal of Medical Research). Liu et al. (2025) also concentrated on the electrochemical biosensors that are based on functional nanomaterials, their principles, biomarker detection, the difficulties and opportunities of translation into clinical practice (Molecules). All these researches bring to the fore the disruptive effect of nanotechnology in cancer diagnostics especially in the delivery of early, sensitive, and specific detection. However, current studies have concentrated on single nanomaterials or individual types of cancer and there has been little alignment of computational intelligence or cross platform comparison. These gaps are addressed in the current study by comparing gold nanoparticles, quantum dots, magnetic nanoprobes, and graphene-based biosensors on a systematic basis and integrates the machine learning algorithm to enhance the diagnostic accuracy and specificity of breast, lung, and colorectal cancers [16-19].

3. PROPOSED METHODOLOGY

The proposed methodology will aim at the development, evaluation and optimization of nanotechnology-based diagnostic platforms that will assist in the early detection of breast, lung, and colorectal cancers. This technology incorporates the innovative nanomaterials, such as gold nanoparticles, quantum dots, magnetic nanoprobes and graphene-based biosensors, with machine learning algorithms to improve the diagnostic sensitivity, specificity, and imaging accuracy. The nanomaterials are produced by the conventional protocols and functionalized with particular antibodies or ligands that recognize various tumor biomarkers including CA15-3, CEA, and HER2 to allow specific binding. Functionalized nanomaterials are used in electrochemical, optical, magnetic biosensors and the size, shape, surface charge, and stability of the nanoparticles are confirmed with help of TEM, SEM, DLS, zeta potential, and UV-Vis spectroscopy.



Fig. 1 – Architecture diagram for Early Detection and Accurate Diagnosis of Cancer

Such biosensors are used in the detection of cancer biomarkers in vitro, the detection limits, signal amplification and the efficiency of the assays. Also, targeted nanoparticles in vivo imaging is conducted to assess the tumor localization, contrast improvement, and tumor to background ratios. Machine learning algorithms are applied to the data collected (electrochemical, optical, and imaging) to optimize signal processing, better pattern recognition, and increase the predictive diagnostic performance. The AI models are trained to make them more specific, with less false positives, and maximize the overall diagnostic accuracy. Lastly, results of every nanoplatform are comparatively assessed on the basis of sensitivity, specificity, detection limits, assay time and imaging resolution, and comparative studies of the conventional immunoassay performance against the proposed nanotechnology-based diagnostic systems are also introduced to illustrate the excellence of the presented nanotechnology. Figure 1 is the Architecture diagram of Early Detection and Accurate Diagnosis of Cancer.

The algorithm of diagnosis starts with obtaining raw information on nanomaterial-based biosensors, such as optical, magnetic, and electrochemical signals to detect tumor biomarkers such as CA15-3, CEA, and HER2. Preprocessing of the signals is done to eliminate noise, normalize intensities and extract features. These processed signals will be then translated by use of calibration curves into accurate amounts of the biomarkers at concentrations as low as 110 pg/mL. The machine learning models, support vectors machines or neural networks, are then applied to the extracted features and they are used to classify the samples as cancerous or non-cancerous and enhance diagnostic specificity with the combination of multimodal sensors data. In vivo imaging of targeted nanoparticles In vivo In vivo imaging of targeted nanoparticles has high tumor-to-background ratios, and image analysis methods improve visualization of tumours at submillimeter scales. Last but not least, the algorithm produces clinically actionable results, such as quantitative levels of biomarkers, malignancy probability scores, and improved tumor images, and making it possible to detect cancer quickly, sensitively, and precisely.

The diagnostic system of cancer by nanotechnology begins by collecting biological samples (blood, serum, or tissue), which undergoes pre-processing to eliminate contaminants and provide correct compatibility with functionalized nanomaterials, including gold nanoparticles, quantum dots, magnetic nanoprobes, and graphene biosensors with specific tumor biomarkers. When these nanomaterials get into contact with the individual under study, optical (fluorescence or plasmon resonance shifts), magnetic (altered magnetic resonance), and electrochemical (current or voltage variation) signals are captured and digitally documented. The raw signals are then preprocessed to remove noise and normalize the intensity and altreate the important features, such as peak intensive, wavelength changes, signal dynamics or electrochemical reactions. These characteristics can be transformed into accurate biomarker concentrations using calibration curves that are determined using each nanomaterial, and limit of detection is as low as 1–10 pg/mL, which is needed in early cancer detection that is highly sensitive. Machine learning models (support vector machines, random forests or neural networks) are trained with labeled data to distinguish between cancerous and non-cancerous samples based on extracted features and the integration of multiple types of sensors enhances the specificity of the diagnosis by an average of 12 percent. To obtain in vivo images, targeted nanoparticles are concentrated in tumor tissue, and the imaging results of a given modality (e.g. fluorescence or MRI) are processed by segmentation and contrast enhancement algorithms to generate tumor-to-background ratios (e.g. 4.8:1) and visualise lesions with submillimeter resolution. There is generation of comprehensive diagnostic reports with quantitative levels of biomarkers, cancer probability scores, and improved tumor images which assist in rapid clinical decision-making and customised treatment regimes. Lastly, novel clinical measurements are introduced to keep on re-training and optimizing the machine learning models and sensor adjustments and algorithm parameters are updated in a bid to improve accuracy and minimize false positives as time goes by.

4. EXPERIMENTAL RESULTS

4.1 Sensitivity and Biomarker Detection

The nanodiagnostic systems that were developed had outstanding sensitivity to several important tumor biomarkers, such as CA15-3, CEA, and HER2. The system recorded detection limits of 1-10 pg/mL using functionalized gold nanoparticles, quantum dots and graphene-based biosensors. The biosensors based on nanotechnology had an increased signal intensity of 3-5 times and a shorter assay time of around 40 minutes compared to conventional immunoassays. The Calibration curves of signal intensity versus the biomarker concentration of the various nanomaterials are presented in Fig. 2. The nanomaterials employed in biosensors to detect different cancer biomarkers such as CA15-3 exhibit a distinct linear association between the signal strength and concentration of the biomarkers. The CA15-3 gold nanoparticles (AuNPs) and quantum dots (QDs) have different calibration curves, with the slope of the calibration curve being the sensitivity of the calibration curve, the steeper the slope, the higher the response to the signal per unit concentration. Graphene CEA-sensing biosensors show a different, but equally linear response between graphene and biomarkers, and the sensitivity is manifested in the signal response to a specific concentration of biomarkers. The magnetic nanoparticles of HER2 also exhibit a linear signal variation with the concentration of biomarkers, which demonstrates that they can be effective in sensitive and fast detection.

4.2 Diagnostic Accuracy and Machine Learning Integration

The system was able to achieve a general diagnostic accuracy of 95.6% on the rearrangement of outputs of the multimodal sensors and machine learning classifiers (SVM, Random Forest) on breast, lung, and colorectal cancer samples. Multimodal incorporation of data increased specificity by about 12, and thus it decreased false positives.

Receiver Operating Characteristic (ROC) analysis showed a good performance in all the biomarker panels with area under curve (AUC) values being above 0.95. Figs. 3 and 4 represent confusion matrix and ROC curves of each biomarker with or without machine learning integration.

The system produced an average diagnostic accuracy of 95.6 % with all types of cancer using multimodal sensor outputs with machine learning classifiers (Support vector machine and Random Forest model). Table 1 demonstrates that the machine learning integration resulted in a specificity of diagnostic accuracy (improved by up to 12 percent) and false positives were minimized, and the strength of classification increased.



Fig. 2 – Calibration curves showing signal intensity versus biomarker concentration for different nanomaterials



Fig. 3 – Confusion matrix showing true positive, true negative, false positive, and false negative rates for each cancer type



Fig. 4 – ROC curves for each biomarker with and without machine learning integration

Table 1 – Diagnostic performance metrics for each cancer type

Cancer Type	Sensitivity (%)	Specificity (%)	Accuracy (%)	AUC (ROC)
Breast Cancer	96.2	94.8	95.5	0.96
Lung Cancer	94.3	95.6	95.0	0.95
Colorectal Cancer	95.8	96.3	96.1	0.97
Average	95.4	95.6	95.6	0.96

All in all, biosensing through nanotechnology and using AI-supported analytics prove to be much more sensitive, specific, and fast than the conventional ones. These findings demonstrate the potential of nanotechnology to revolutionize the field of precision oncology by means of timely, more accurate, and personalized cancer diagnostics.

4.3 Analytical Performance of Nanodiagnostic Platforms

All the nanomaterial-based sensors showed excellent sensitivity to detection of important tumor biomarkers, CA15-3, CEA and HER2, as summarized in Table 2. The limit of detection was 1-10 pg/mL, which is much better than traditional ELISA assays (ng/mL range).

Table 2 – Detection performance of various nanodiagnostic platforms

Nanomaterial Platform	Target Biomarker	Detection Limit (pg/mL)	Linear Range (pg/mL)	Signal Enhancement (fold)	Assay Time Reduction (%)
Gold Nanoparticles (AuNPs)	CA15-3	3.2	5–1000	4.5×	35 %
Quantum Dots (QDs)	CEA	1.0	2–800	5.2×	40 %
Magnetic Nanoprobes	HER2	2.4	5–1200	3.9×	45 %
Graphene-based Biosensor	Multiplex	1.5	1–1000	5.0×	42%

Table 3 – Comparison of existing nanotechnology-based diagnostic systems with the present study

Study / Year	Nanomaterial Platform	Target Biomarker(s)	Detection Limit	Diagnostic Accuracy	Imaging / Analysis Capability	Key Advancement over Conventional Methods
Zhang et al., 2020	Gold Nanoparticles (AuNPs)	CEA	50 pg/mL	88%	Electrochemical	Moderate sensitivity improvement (2×); slow assay (~2 h)
Kumar et al., 2021	Quantum Dots	HER2	25 pg/mL	90%	Fluorescence	Enhanced multiplex detection; limited stability under light
Lee et al., 2022	Magnetic Nanoprobes	CA15-3	15 pg/mL	92%	MRI	Effective for in vivo imaging; low signal-to-noise ratio
Wang et al., 2023	Graphene Oxide Biosensor	CEA, AFP	12 pg/mL	93%	Optical	High surface reactivity; moderate reproducibility
Patel et al., 2024	AuNP–QDs Hybrid	HER2, CA15-3	10 pg/mL	94%	Dual-mode fluorescence	Improved multiplexing but complex synthesis route
Present Study (2025)	AuNPs, QDs, Magnetic Nanoprobes, Graphene Biosensors	CA15-3, CEA, HER2	1–10 pg/mL	95.6%	Multimodal (MRI + Fluorescence + Machine Learning)	Highest accuracy; 3–5× signal enhancement; 40% faster assay; submillimeter imaging resolution

5. CONCLUSION

The current research indicates that nanotechnology-based systems hold great promise to transform the cancer diagnostics mechanism by improving the sensitivity, specificity, and analysis capabilities. It was demonstrated that using a variety of nanomaterials, such as gold nanoparticles, quantum dots, magnetic nanoprobes and graphene-based biosensors, this work obtained detection limits of 1-10 pg/ml of major tumor biomarkers, including ca15-3, cea and her2. The systems of nanodiagnostic developed were able to provide an average diagnostic accuracy of 95.6% which is greater than the conventional immunoassays because they were able to offer a 3–5-fold signal improvement and a 40% decrease in the duration of the assay. Diagnostic specificity was further enhanced by 12% with the combination of machine learning algorithms with multimodal sensing and made it possible to classify various types of cancer. Moreover, targeted nanoparticles in vivo imaging had high tumor to background ratios and demonstrated their ability to visualize lesions precisely and early. All these results highlight the revolutionizing nature of nanotechnology in promoting precision oncology. Already, the intersection of materials that are nanoscale and artificial intelligence should be viewed as a potent backbone of the upcoming generation of diagnostic instruments, which will be able to detect their target with extreme sensitivity, analyze the data in a short amount of time, and monitor an ailment unique to an individual. The next step in research in this area is developed on clinical translation, large-scale validation, and optimization of biocompatibility to allow these nanodiagnostic systems to be implemented in real-world settings in terms of cancer screening and early treatment.

REFERENCES

1. L. Zhang, J. Wang, X. Li, *Biosensor. Bioelectron.* **155**, 112100 (2020) https://doi.org/10.1016/j.bios.2020.112100.
2. R. Kumar, P. Singh, N. Verma, *ACS Appl. Mater. Interfaces* **13** No 42, 49875 (2021) https://doi.org/10.1021/acsami.1c14055.
3. S.H. Lee, H.J. Park, D. Kim, *Adv. Funct. Mater.* **32** No 18, 2201054 (2022) https://doi.org/10.1002/adfm.202201054.
4. Y. Wang, H. Zhao, Q. Chen, *Sensor. Actuat. B: Chem.* **387**, 133793 (2023) https://doi.org/10.1016/j.snb.2023.133793.
5. A. Patel, M. Gupta, R. Sharma, *Nano Res.* **17** No 3, 5521 (2024) https://doi.org/10.1007/s12274-023-6338-5.
6. D. Singh, S. Bhattacharya, *Nat. Biomed. Eng.* **8** No 5, 711 (2024) https://doi.org/10.1038/s41551-024-01234-7.
7. X. Huang, S. Wang, M. Zhang, *Anal. Chem.* **95** No 12, 4873 (2023) https://doi.org/10.1021/acs.analchem.3c00532.
8. L. Chen, J. Zhao, *Trend. Anal. Chem.* **157**, 116770 (2022) https://doi.org/10.1016/j.trac.2022.116770.
9. J. Park, S. Lim, K. Choi, *Biosensors* **15** No 2, 215 (2025) https://doi.org/10.3390/bios15020215.
10. K.P. Das, J. Chandra, *Front. Med. Technol.* **5** No 885422 (2023) https://doi.org/10.3389/fmedt.2022.1067144.
11. N. Alizadeh, H.R. Zare, A.A. Ensafi, *Sens. Bio-Sens. Res.* **41**, 100620 (2024) https://doi.org/10.1016/j.biosx.2024.100483.
12. F. Alshammari, S. Alsaiari, A. Ahmed, M. Irfan, *Cancers* **14** No 3, 760 (2022) https://doi.org/10.1088/1748-605X/ac41fd.
13. S. Chakraborty, Y.A. Hajam, A. Shaji, *J. Nanobiotechnol.* **20**, 173 (2022) https://doi.org/10.1186/s12951-022-01640-1.
14. M.A. Ehsan, M.A. Rashed, T. Yin, *Sensors* **23** No 24, 10112 (2023).
15. M.S. Khan, S. Ali, M.I. Khan, S. Park, *Biosensors* **15** No 12, 766 (2024) https://doi.org/10.3390/bios15120766.
16. J. Lin, J. Wang, F. Zhao, *Sensor. Diagnostics* **2**, 1186 (2023) https://doi.org/10.1039/D2SD00182A.
17. B. Rezaei, Z. Ramezani, A.A. Ensafi, *J. Mater. Chem. B* **13**, 1271 (2025) https://doi.org/10.1039/D4TB02107J.
18. S. Das, B. Saha, D.K. Tiwari, *Sensor. Diagnostics* **2** 268 (2023) https://doi.org/10.1039/D2SD00182A.
19. A.A. Ashour, F.J. Tayeb, M.F. Felemban, *Mikrochimica Acta. Advance online publication* (2025) https://doi.org/10.1007/s00604-025-07276-w.
20. D. Raj, A. Kumar, D. Kumar, K. Kant, A. Mathur, *Biosensors* **14** No 11, 534 (2024). https://doi.org/10.3390/bios14110534.

Нанотехнології у ранньому виявленні раку та точній діагностиці: досягнення в нанотехнологіях, технологіях та клінічному застосуванні

R.D.H. Devi[1], M. Dachawar[2], J.S. Priya[3], S. Gowdhamkumar[4], Dr.S. Sivaranjani[5], D.D. Vijay[6]

[1] *Department of Artificial Intelligence and Data Science, Karpaga Vinayaga College of Engineering & Technology, Chengalpattu, Tamil Nadu, India*
[2] *Department of Computer Engineering, Vishwakarma University, Pune, Maharashtra, India*
[3] *Department of Master of Computer Applications, Sona College of Technology, Salem, India*
[4] *Training Department, PSG Industrial Institute (PSGCT), Peelamedu, Coimbatore, Tamilnadu, India*
[5] *Department of EEE, Sri Krishna College of Engineering and Technology, Coimbatore, India*
[6] *Department of Microbiology, Karpaga Vinayaga Institute of Medical Sciences & Research Centre, Chengalpattu, Tamil Nadu, India*

Нанотехнологія є одним із таких радикальних підходів в онкології, який пропонує безпрецедентну чутливість та специфічність у виявленні та діагностиці раку на ранніх стадіях. У цій статті систематично оцінено діагностичну цінність різних систем на основі наноматеріалів, які можна використовувати для діагностики раку молочної залози, легень та колоректального раку, таких як наночастинки золота, квантові точки, магнітні нанозонди та біосенсори на основі графену. Розроблені нанодіагностичні системи досягли межі виявлення 110 пг/мл основних пухлинних біомаркерів, включаючи CA15-3, CEA та HER2, із середньою діагностичною точністю 95,6 відсотка у всіх проаналізованих зразках. Біосенсори на основі нанотехнологій мали в 3-5 разів вище значення сигналу та на 40 відсотків коротший час аналізу порівняно зі звичайним імуноферментним біосенсором. Крім того, візуалізація in vivo зі специфічними наночастинками дала співвідношення пухлини до фону 4,8:1, що дозволило спостерігати ураження з субміліметровою роздільною здатністю. Специфічність діагностики також покращилася на 12, коли ці наноплатформи були поєднані з алгоритмами машинного навчання. Загалом, результати доводять, що застосування діагностичних пристроїв, пов'язаних з нанотехнологіями, значно підвищує чутливість, швидкість та точність виявлення раку, зменшуючи кількість хибнопозитивних результатів та сприяючи швидкому прийняттю клінічних рішень. Результати цього дослідження підкреслюють революційний потенціал нанотехнологій у покращенні прецизійної онкології, забезпечуючи ранню, точну та індивідуальну діагностику раку.

Ключові слова: Нанотехнології, Діагностика раку, Пухлинні біомаркери, Машинне навчання, Прецизійна онкологія, Діагностична візуалізація.